Osimertinib induced adverse cardiac events: a case report
Open Access
- 1 September 2023
- journal article
- letter
- Published by Tsinghua University Press in Journal of Geriatric Cardiology
- Vol. 20 (9) , 702-706
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor OsimertinibJACC: Cardiooncology, 2020
- Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With OsimertinibJACC: Cardiooncology, 2020
- Osimertinib-Induced CardiotoxicityJACC: Cardiooncology, 2019
- Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with OsimertinibClinical Cancer Research, 2018
- Development of Heart Failure After Initiation of Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-Mutant Adenocarcinoma of the LungThe American Journal of Cardiology, 2018
- Cardiac Dysfunction Caused by OsimertinibJournal of Thoracic Oncology, 2017
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerNew England Journal of Medicine, 2017
- Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)Internal Medicine, 2017
- Expression and Function of the Epidermal Growth Factor Receptor in Physiology and DiseasePhysiological Reviews, 2016
- Systems biology approaches to adverse drug effects: the example of cardio-oncologyNature Reviews Clinical Oncology, 2015